G Ji1,2, R Xu3, Y Niu1,2, N Li3, L Ivashkiv2, M P G Bostrom2,4, M B Greenblatt2,5, X Yang2. 1. Department of Joint Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, China. 2. Research Division, Hospital for Special Surgery, New York, New York, USA. 3. Department of Orthopedics, Xiang'an Hospital and State Key Laboratory of Cellular Stress Biology, School of Medicine, Xiamen University, Xiamen, China. 4. Division of Adult Reconstruction and Joint Replacement, Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, New York, USA. 5. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Cornell University, New York, New York, USA.
Abstract
AIMS: It is increasingly appreciated that coordinated regulation of angiogenesis and osteogenesis is needed for bone formation. How this regulation is achieved during peri-implant bone healing, such as osseointegration, is largely unclear. This study examined the relationship between angiogenesis and osteogenesis in a unique model of osseointegration of a mouse tibial implant by pharmacologically blocking the vascular endothelial growth factor (VEGF) pathway. MATERIALS AND METHODS: An implant was inserted into the right tibia of 16-week-old female C57BL/6 mice (n = 38). Mice received anti-VEGF receptor-1 (VEGFR-1) antibody (25 mg/kg) and VEGF receptor-2 (VEGFR-2) antibody (25 mg/kg; n = 19) or an isotype control antibody (n = 19). Flow cytometric (n = 4/group) and immunofluorescent (n = 3/group) analyses were performed at two weeks post-implantation to detect the distribution and density of CD31hiEMCNhi endothelium. RNA sequencing analysis was performed using sorted CD31hiEMCNhi endothelial cells (n = 2/group). Osteoblast lineage cells expressing osterix (OSX) and osteopontin (OPN) were also detected with immunofluorescence. Mechanical pull-out testing (n = 12/group) was used at four weeks post-implantation to determine the strength of the bone-implant interface. After pull-out testing, the tissue attached to the implant surface was harvested. Whole mount immunofluorescent staining of OSX and OPN was performed to determine the amount of osteoblast lineage cells. RESULTS: Flow cytometry revealed that anti-VEGFR treatment decreased CD31hiEMCNhi vascular endothelium in the peri-implant bone versus controls at two weeks post-implantation. This was confirmed by the decrease of CD31 and endomucin (EMCN) double-positive cells detected with immunofluorescence. In addition, treated mice had more OPN-positive cells in both peri-implant bone and tissue on the implant surface at two weeks and four weeks, respectively. More OSX-positive cells were present in peri-implant bone at two weeks. More importantly, anti-VEGFR treatment decreased the maximum load of pull-out testing compared with the control. CONCLUSION: VEGF pathway controls the coupling of angiogenesis and osteogenesis in orthopaedic implant osseointegration by affecting the formation of CD31hiEMCNhi endothelium. Cite this article: Bone Joint J 2019;101-B(7 Supple C):108-114.
AIMS: It is increasingly appreciated that coordinated regulation of angiogenesis and osteogenesis is needed for bone formation. How this regulation is achieved during peri-implant bone healing, such as osseointegration, is largely unclear. This study examined the relationship between angiogenesis and osteogenesis in a unique model of osseointegration of a mouse tibial implant by pharmacologically blocking the vascular endothelial growth factor (VEGF) pathway. MATERIALS AND METHODS: An implant was inserted into the right tibia of 16-week-old female C57BL/6 mice (n = 38). Mice received anti-VEGF receptor-1 (VEGFR-1) antibody (25 mg/kg) and VEGF receptor-2 (VEGFR-2) antibody (25 mg/kg; n = 19) or an isotype control antibody (n = 19). Flow cytometric (n = 4/group) and immunofluorescent (n = 3/group) analyses were performed at two weeks post-implantation to detect the distribution and density of CD31hiEMCNhi endothelium. RNA sequencing analysis was performed using sorted CD31hiEMCNhi endothelial cells (n = 2/group). Osteoblast lineage cells expressing osterix (OSX) and osteopontin (OPN) were also detected with immunofluorescence. Mechanical pull-out testing (n = 12/group) was used at four weeks post-implantation to determine the strength of the bone-implant interface. After pull-out testing, the tissue attached to the implant surface was harvested. Whole mount immunofluorescent staining of OSX and OPN was performed to determine the amount of osteoblast lineage cells. RESULTS: Flow cytometry revealed that anti-VEGFR treatment decreased CD31hiEMCNhi vascular endothelium in the peri-implant bone versus controls at two weeks post-implantation. This was confirmed by the decrease of CD31 and endomucin (EMCN) double-positive cells detected with immunofluorescence. In addition, treated mice had more OPN-positive cells in both peri-implant bone and tissue on the implant surface at two weeks and four weeks, respectively. More OSX-positive cells were present in peri-implant bone at two weeks. More importantly, anti-VEGFR treatment decreased the maximum load of pull-out testing compared with the control. CONCLUSION: VEGF pathway controls the coupling of angiogenesis and osteogenesis in orthopaedic implant osseointegration by affecting the formation of CD31hiEMCNhi endothelium. Cite this article: Bone Joint J 2019;101-B(7 Supple C):108-114.
Authors: Jared M Newman; Nipun Sodhi; Joanne C Dekis; Anton Khlopas; Nicolas S Piuzzi; Assem A Sultan; Jay M Levin; Michael A Mont Journal: J Knee Surg Date: 2019-02-08 Impact factor: 2.757
Authors: Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras Journal: Bioinformatics Date: 2012-10-25 Impact factor: 6.937
Authors: Ren Xu; Alisha Yallowitz; An Qin; Zhuhao Wu; Dong Yeon Shin; Jung-Min Kim; Shawon Debnath; Gang Ji; Mathias P Bostrom; Xu Yang; Chao Zhang; Han Dong; Pouneh Kermani; Sarfaraz Lalani; Na Li; Yifang Liu; Michael G Poulos; Amanda Wach; Yi Zhang; Kazuki Inoue; Annarita Di Lorenzo; Baohong Zhao; Jason M Butler; Jae-Hyuck Shim; Laurie H Glimcher; Matthew B Greenblatt Journal: Nat Med Date: 2018-05-21 Impact factor: 53.440
Authors: Anita Sanghani-Kerai; Melanie Coathup; Robyn Brown; George Lodge; Liza Osagie-Clouard; Ian Graney; John Skinner; Panogiotis Gikas; Gordon Blunn Journal: Bone Joint Res Date: 2020-08-19 Impact factor: 5.853
Authors: Yunwei Xia; Upneet K Sokhi; Richard D Bell; Tania Pannellini; Kathleen Turajane; Yingzhen Niu; Laura Frye; Max Chao; Ugur Ayturk; Miguel Otero; Mathias Bostrom; David Oliver; Xu Yang; Lionel B Ivashkiv Journal: J Bone Miner Res Date: 2021-06-20 Impact factor: 6.390
Authors: Kevin Staats; Branden R Sosa; Emile-Victor Kuyl; Yingzhen Niu; Vincentius Suhardi; Kathleen Turajane; Reinhard Windhager; Matthew B Greenblatt; Lionel Ivashkiv; Mathias P G Bostrom; Xu Yang Journal: Bone Joint Res Date: 2022-05 Impact factor: 4.410